Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound anisodine plus anti-VEGF for branch retinal vein occlusion macular edema
ChiCTR-IPR-16009197Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anisodine in branch retinal vein occlusion (BRVO) and macular edema (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Best corrected visual acuity. Started Apr 2016; status: recruiting.
02
Drugs
anisodine
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on ChiCTR-IPR-16009197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009197.